The forum’s goal this year is to deepen the Search for public-private partnerships between government and pharmaceutical companies for the production of biosimilars focusing on the efforts that have been made by the National Government at the head of the public sector and private industries; aimed at exploring alliances in search of technology transfers that allow the production of vaccines, biosimilars, development of technology for cancer among others.

These alliances are not new in the region, they are well known in Brazil as Partnerships for Productive Development (PPD) and recently in Mexico they have been implemented for the production of Covid vaccines; which suggests a trend in the region in search of expansion, development and investment that will ultimately benefit patients with the introduction of therapeutic options that can help to overcome the access disparities that our region and Colombia currently has.

Who will
you meet?

More than:

Participants

Companies

HCPs

Patients

Academy

Investors

Institutions

Associations

Service Providers

Government Agencies

Industry Executives from Latam

From these areas:

Biosimilars
Biobetters
Biotechnology
Biotherapeutics
Analytical science
Regulatory compliance
Quality Control
Clinical immunology
Scientific Affairs
Pharmacovigilance
Research
Regulatory
Business Development
Marketing

Speaker Board

Program at a Glance

Regulatory Update: Worldwide Overview

The discussion from 2021 about Biosimilars production in LatAm continues including the important key factors such as The Development of a broader Regulatory Framework and a long-term pharmaceutical policy.

Technology Transfer Challenges and Opportunities

Exploring technology transfer opportunities, overcoming the challenges and inspiring Colombia by other LatAm countries to take the leap when it comes to launching the production and development of Biosimilars

Case Study: Dispensers Role in PV

The best-practices and improvement overview directly from Healthcare professionals to secure the traceability of medicaments and ability to track the patient’s medical journey. Securing the ability to reacting promptly in case any adverse-effects happen and be able to change the cure knowing exactly the root of the problem

Patient-centered Communication

When it comes to accessing the relevant information about biosimilars in general, for some countries there is always room for improvement. In this panel, we will ease the process of bringing the necessary knowledge and awareness to build confidence in these medicaments.

Tendering Procedures: LatAm Overview

Sharing the overview of the different tendering systems within the countries in Latin America. Regulatory frameworks differences and best practices to comply with neccessary requirements considering the wide expertise. Transparent tender models, their advantages and those aspects that could be improved to increase and provide the access of life-saving medications to patients.

Biosimilars Market Innovation: from Developing a Mindset for Global Competitiveness to Business Strategies

Business talks: The local Biosimilar market and its innovations development using the right commercial strategies and a mindset for a global competitiveness.

Full programme in the PDF Agenda

Download Agenda

Download Agenda

Proccess Filtration R&M Colombia

Technically and commercially support the country’s industrial sector. Providing knowledge and experience to the food and beverage, cosmetic and pharmaceutical industry in separation, purification and filtration processes of critical fluids, as well as water, finished product, air lines, steam and venting.

Representatives of the main brands worldwide that are leaders in filtration, separation and purification processes, the support of allies in the United States and Asia to supply the consumption and logistics chain of our clients, complying with high quality standards.

Visit Website

Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros according to preliminary figures. At the end of 2019, more than 9,000 people work at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.

Visit Website

Cytiva

Cytiva is a global provider of technologies and services that help advance and accelerate the development and production of therapeutic products. Promoting training, speed and efficiency for research and production workflows, allowing the delivery of innovative medicines to patients.

Visit Website

Sponsor the Forum

Photo Gallery from Previous Events

Open Gallery

Testimonials

”It was an excellent opportunity to hear what the authorities industry, even sometimes what our competitors or other providers have to say about the topic.”

Alison Bascou, Sr. Regulatory Director at BD, France
"I think it's being an interesting event. Wherever there's discussion at top level, wherever there's respect. wherever there's an open forum, science can advance. It's very important to keep patient's well-being in mind and I think this forum allows that."

Jaime Uribe, CEO At PROBIOMED
“The strength of the biosimilar industry in our region is very encouraging. It seems to me this event is the propitious forum to share experiences and it is great.”

Tammy Boggiano Ayo, Process Development Director at CIM, Cuba
“It showed a broad picture, from a highly technical perspective up to a commercial viewpoint. It is not easy to get that in such a short period of time.”

Santiago Salguero, Executive Director at Pharmaceutical Association of Ecuador
“For companies like those I work for, i.e. suppliers to the pharmaceutical industry, this has been a great opportunity to see our clients’ perspective and above all to identify the major trends determining the future of biosimilars.”

Mauricio Roberto Hernández Morales, Key Account and Business Developer Manager at BD Mexico